Amphastar Pharmaceuticals, Inc. (AMPH) Stock

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. is led by CEO Yongfeng Zhang, employs 2,028 people, headquartered in US, publicly traded since 2014.

Amphastar Pharmaceuticals, Inc. (AMPH) stock trades at $25.14 with a market capitalization of $1.07B. The stock is valued at a price-to-earnings (P/E) ratio of 14.50, price-to-book of 1.43, price-to-sales of 1.52. Over the past 52 weeks the stock has ranged between $16.65 and $29.52, and currently trades 14.8% below its 52-week high.

On profitability, Amphastar Pharmaceuticals, Inc. generates a return on equity (ROE) of 10.11%, return on capital employed of 7.72%, an operating margin of 16.20%, a net profit margin of 10.76%.

Amphastar Pharmaceuticals, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Amphastar Pharmaceuticals, Inc. reported revenue of $255.0M rising to $720.0M, a change of +182.4% across 10 years. Compounded, revenue has grown 15.5% a year over five years, 13.0% over three, -1.6% over the last twelve months. Net profit rose to $98.0M.

Operating margin went from 6.2% in 2016 to 19.5% in 2025, a gain of 13.3 percentage points. The most recent net margin is 10.76%. On a trailing twelve-month basis to Jun '26, revenue is $730.0M and net profit $77.0M.

Borrowings rose from $38.0M to $656.0M, cash from operations was $156.0M in the latest year, positive in 10 of the last 10.

Return on equity has averaged 17.4% over five years, and was 12.4% in the most recent year.

The share price itself has compounded at -0.2% a year over five years, -28.7% over three, -22.7% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Amphastar Pharmaceuticals, Inc. (AMPH) — frequently asked questions